Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
NUVL Stock Chart & Stats
$102.67
-$0.36(-0.45%)
At close: 4:00 PM EST
$102.67
-$0.36(-0.45%)
Day’s Range― - ―
52-Week Range$55.54 - $112.88
Previous CloseN/A
Volume65.93K
Average Volume (3M)487.40K
Market Cap
$7.46B
Enterprise Value$5.30B
Total Cash (Recent Filing)$943.10M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Mar 04, 2026EPS Estimate
-1.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding67,271,460
10 Day Avg. Volume443,514
30 Day Avg. Volume487,403
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-28.09
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.98
Forecast
1Y Price Target
$140.86Price Target Upside37.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial ProspectsThe company is well-positioned to become a commercial entity by the end of 2026 as zildesamtinib is expected to receive accelerated approval as a therapy for ROS1-positive NSCLC.
Financial PositionWith a strong balance sheet and management focused on executing their strategy, the stock is considered undervalued and provides an opportunity for a long-term investor.
Therapeutic DevelopmentsNuvalent reported positive topline data from the ongoing ALKOVE-1 study which paves the way for neladalkib to be filed as a 2L therapy for ALK-positive NSCLC patients.
Bears Say
Nuvalent News
NUVL FAQ
What was Nuvalent’s price range in the past 12 months?
Nuvalent lowest stock price was $55.53 and its highest was $112.88 in the past 12 months.
What is Nuvalent’s market cap?
Nuvalent’s market cap is $7.46B.
When is Nuvalent’s upcoming earnings report date?
Nuvalent’s upcoming earnings report date is Mar 04, 2026 which is in 53 days.
How were Nuvalent’s earnings last quarter?
Nuvalent released its earnings results on Oct 30, 2025. The company reported -$1.7 earnings per share for the quarter, missing the consensus estimate of -$1.387 by -$0.313.
Is Nuvalent overvalued?
According to Wall Street analysts Nuvalent’s price is currently Undervalued.
Does Nuvalent pay dividends?
Nuvalent does not currently pay dividends.
What is Nuvalent’s EPS estimate?
Nuvalent’s EPS estimate is -1.48.
How many shares outstanding does Nuvalent have?
Nuvalent has 67,271,460 shares outstanding.
What happened to Nuvalent’s price movement after its last earnings report?
Nuvalent reported an EPS of -$1.7 in its last earnings report, missing expectations of -$1.387. Following the earnings report the stock price went down -4.662%.
Which hedge fund is a major shareholder of Nuvalent?
Currently, no hedge funds are holding shares in NUVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvalent Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$140.86 (37.20% Upside)
$140.86 (37.20% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $70.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.20%
12-Months-Change
Fundamentals
Return on Equity
-38.79%
Trailing 12-Months
Asset Growth
-17.58%
Trailing 12-Months
Company Description
Nuvalent
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL Stock 12 Month Forecast
Average Price Target
$140.86
▲(37.20% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---